Fox Leanne M
Division of Infectious Diseases, Children's Hospital, Boston, Massachusetts 02115, USA.
Curr Opin Infect Dis. 2006 Dec;19(6):588-93. doi: 10.1097/QCO.0b013e328010774c.
Ivermectin was first discovered and used in veterinary medicine over 20 years ago. This review highlights some of the recent published research from 2005 through June 2006 on the use of ivermectin in both helminth and arthropod infection.
In recent years, several published studies have detailed the expanding role for ivermectin in multiple endo and ectoparasitic infections, including scabies, pediculosis, soil transmitted helminths, gnathostomiasis and myiasis. In addition, there is increasing experience with parenteral ivermectin for the treatment of disseminated strongyloidiasis. The success of ivermectin in reducing Onchocerca volvulus and Wuchereria bancrofti transmission through universal treatment in disease control programs continues to be well documented, but recent epidemiologic data describe suboptimal response to ivermectin by O. volvulus in a minority of individuals, the molecular markers for which are currently under investigation.
Over 20 years of research and clinical use have advanced ivermectin from its beginnings as a veterinary anthelmintic to its significant role in several successful disease control programs. Nevertheless, further research is needed to understand the basis for suboptimal response and to better define optimal drug regimens for varying diseases.
伊维菌素于20多年前首次被发现并应用于兽医学。本综述重点介绍了2005年至2006年6月期间发表的一些关于伊维菌素在蠕虫和节肢动物感染中应用的最新研究。
近年来，多项已发表的研究详细阐述了伊维菌素在多种体内和体外寄生虫感染中的作用不断扩大，包括疥疮、虱病、土壤传播的蠕虫感染、颚口线虫病和蝇蛆病。此外，肠外使用伊维菌素治疗播散性类圆线虫病的经验也在增加。在疾病控制项目中，通过普遍治疗，伊维菌素成功减少盘尾丝虫和班氏吴策线虫传播的情况仍有充分记录，但最近的流行病学数据表明，少数个体对伊维菌素治疗盘尾丝虫的反应欠佳，目前正在对其分子标记进行研究。
经过20多年的研究和临床应用，伊维菌素已从最初作为兽用驱虫药发展到在多个成功的疾病控制项目中发挥重要作用。然而，仍需要进一步研究以了解反应欠佳的原因，并更好地确定针对不同疾病的最佳用药方案。
